TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05971602
Drug: Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS)
DrugBank: Bedaquiline (DB08903)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: D- 300 milligram (mg) once daily (QD) for treatment duration; B- 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S- 1200 mg QD for treatment duration
Study: NCT05971602
Drug: Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS)
DrugBank: Pretomanid (DB05154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P- 200 mg QD for treatment duration; B- 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S- 1200 mg QD for treatment duration
Study: NCT05971602
Drug: Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS)
DrugBank: Pretomanid (DB05154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: X - Pretomanid 200 mg QD for treatment duration OR Delamanid 300 mg QD for treatment duration; B - 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S-1200 mg QD for treatment duration
Study: NCT05971602
Drug: Isoniazid and Rifampicin (HR)
Normalized name: rifampicin and isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed dose combination (FDC) of 75 mg of isoniazid and 150 mg of rifampicin (HR) (Standard of Care \[SOC\]). All the doses administered will be weight-based.
Study: NCT04846452
Drug: Sintilimab + Anlotinib + Pemetrexed + Cisplatin or Carboplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with non-squamous NSCLC will receive sintilimab, anlotinib hydrochloride, pemetrexed, and cisplatin or carboplatin.
Study: NCT04846452
Drug: Sintilimab + Anlotinib + Albumin Paclitaxel + Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients with squamous NSCLC will receive sintilimab, anlotinib hydrochloride, albumin paclitaxel, and carboplatin.
Study: NCT05862012
Drug: ISB 2001
Normalized name: ISB 2001
DrugBank: ISB 2001 (DB18570)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive escalating doses of ISB 2001
Study: NCT05862012
Drug: ISB 2001
Normalized name: ISB 2001
DrugBank: ISB 2001 (DB18570)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive injection of ISB 2001 as determined in Part 1.
Study: NCT05059223
Drug: AXS-12 (reboxetine)
Normalized name: AX
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AXS-12 tablets, taken twice daily
Study: NCT02802423
Drug: BLEX 404 Oral Liquid
Normalized name: Bleximenib
DrugBank: Bleximenib (DB19328)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLEX 404 Oral Liquid is administered twice daily during the Docetaxel monotherapy period. The dose of Docetaxel is 75 mg/m2 IV, 21 days a cycle.
Study: NCT05359133
Drug: Tetrodotoxin
Normalized name: Tetrodotoxin
DrugBank: Tetrodotoxin (DB05232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTX for Injection, 30 µg/mL, is a sterile, nonpyrogenic, white, lyophilized powder provided in a 5 mL glass single-use vial with a rubber stopper and aluminum overseal. Upon reconstitution of the lyophilized product with 1.1 mL of sterile water for injection, each vial delivers 1 mL of fluid containing 30 µg of TTX with a pH of 4.0 to 5.5
Study: NCT06524570
Drug: ICI
Normalized name: Ficin
DrugBank: Taraxacum officinale pollen (DB10755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab and nivolumab
Study: NCT06109272
Drug: Livmoniplimab
Normalized name: Livmoniplimab
DrugBank: Livmoniplimab (DB18939)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Solution
Study: NCT06109272
Drug: Budigalimab
Normalized name: Budigalimab
DrugBank: Budigalimab (DB16668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Solution
Study: NCT06109272
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV) Solution
Study: NCT06109272
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous (IV) Solution
Study: NCT06109272
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV) Solution
Study: NCT06109272
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Solution
Study: NCT05496686
Drug: 4.7 microCi 225Ac-MTI-201
DrugBank: MTI-201 (DB17169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.7 microCi intravenous solution
Study: NCT05496686
Drug: 9.5 microCi of 225Ac-MTI-201
DrugBank: MTI-201 (DB17169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.5 microCi intravenous solution
Study: NCT05496686
Drug: 19 microCi of 225Ac-MTI-201
Normalized name: Oil of peppermint
DrugBank: MTI-201 (DB17169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19 microCi intravenous solution
Study: NCT05496686
Drug: 38 microCi of 225Ac-MTI-201
Normalized name: Oil of peppermint
DrugBank: MTI-201 (DB17169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 38 microCi intravenous solution
Study: NCT05496686
Drug: 76 microCi of 225Ac-MTI-201
Normalized name: Oil of peppermint
DrugBank: MTI-201 (DB17169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 76 microCi intravenous solution
Study: NCT05496686
Drug: 152 microCi of 225Ac-MTI-201
Normalized name: Oil of peppermint
DrugBank: MTI-201 (DB17169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 152 microCi intravenous solution
Study: NCT05496686
Drug: 254 microCi of 225Ac-MTI-201
Normalized name: Oil of peppermint
DrugBank: MTI-201 (DB17169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 254 microCi intravenous solution
Study: NCT05496686
Drug: 424 microCi of 225Ac-MTI-201
Normalized name: Oil of peppermint
DrugBank: MTI-201 (DB17169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 424 microCi intravenous solution
Study: NCT05496686
Drug: 564 microCi of 225Ac-MTI-201
Normalized name: Oil of peppermint
DrugBank: MTI-201 (DB17169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 564 microCi intravenous solution
Study: NCT05496686
Drug: 750 microCi of 225Ac-MTI-201
Normalized name: Oil of peppermint
DrugBank: MTI-201 (DB17169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 microCi intravenous solution
Study: NCT05496686
Drug: 998 microCi of 225Ac-MTI-201
Normalized name: Oil of peppermint
DrugBank: MTI-201 (DB17169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 998 microCi intravenous solution
Study: NCT05496686
Drug: 1327 microCi of 225Ac-MTI-201
Normalized name: Oil of peppermint
DrugBank: MTI-201 (DB17169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1327 microCi intravenous solution
Study: NCT05353257
Drug: HLX10
Normalized name: Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal hlx10 .gamma.4-chain), disulfide with human-mus musculus monoclonal hlx10 .kappa.-chain, dimer
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serplulimab is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~300mg Q3W
Study: NCT05353257
Drug: carboplatin/cisplatin-etoposide
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etoposide: 100 mg/m2, IV, on Days 1, 2, and 3 of each cycle. Carboplatin: AUC = 5, IV, on Day 1 of each cycle up to a dose of 750 mg. investigator's choice.~Cisplatin: 75mg/m2, IV, on Days 1 of each cycle. investigator's choice.
Study: NCT06237920
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction with immune checkpoint blockade nivolumab on day 1. Nivolumab will also be administered on day 29. Response evaluation will be after the last cycle of checkpoint inhibition.
Study: NCT06237920
Drug: Relatlimab
Normalized name: Relatlimab
DrugBank: Relatlimab (DB14851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction with immune checkpoint blockade nivolumab and relatlimab on day 1. Nivolumab and relatlimab will also be administered on day 29. Response evaluation will be after the last cycle of checkpoint inhibition.
Study: NCT05753930
Drug: Imlifidase
Normalized name: Imlifidase
DrugBank: Imlifidase (DB15258)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
Study: NCT04919226
Drug: 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT
Normalized name: edotreotride
DrugBank: Edotreotide (DB17969)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-edotreotide with a defined number of cycles will be administered.
Study: NCT04919226
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
Study: NCT04919226
Drug: FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
Study: NCT05008484
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000IU oral vitamin D supplementation daily for 9 months
Study: NCT04971785
Drug: Cilofexor (CILO)/Firsocostat (FIR)
DrugBank: Cilofexor (DB15168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT06315283
Drug: TV-44749
Normalized name: Tv-3326 free base
DrugBank: Ladostigil (DB16213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (sc)
Study: NCT06315283
Drug: Oral olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05153668
Drug: Everolimus Oral Tablet
Normalized name: everolimus Oral Tablet
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus 1.5mg by mouth daily will be given for 42 days after dilation surgery.
Study: NCT04902443
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide will be administered as an oral planned starting dose of 3 mg daily (dose escalation) or at an MTD of 4 mg (dose expansion). Pomalidomide will be given from day 1 to day 21 of each cycle.
Study: NCT04902443
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be administered IV at a dose of 480 mg at day one of each cycle, except for cycle one when it will be administered on day 8. One cycle equals 28 days
Study: NCT05662904
Drug: Gemtuzumab Ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intrapatient intra-individual dose escalation Level 0: GO day 1 Level 1: GO day 1, day 4 Level 2: GO day 1, day 4, day 7 with repetition after 21 to 28 days up to 84 days.
Study: NCT05061719
Drug: Lumateperone
Normalized name: Lumateperone
DrugBank: Lumateperone (DB06077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lumateperone 42 mg capsules administered orally, once daily
Study: NCT06111872
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration described in arm/ group description
Study: NCT06111872
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration described in arm/ group description
Study: NCT06111872
Drug: Pethidin
Normalized name: Pethidin
DrugBank: Meperidine (DB00454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration described in arm/ group description
Study: NCT05909761
Drug: UPLIZNA
Normalized name: Uplizna
DrugBank: Inebilizumab (DB12530)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enrolled female participants with NMOSD who were exposed to UPLIZNA during pregnancy will be assessed. No study drug will be administered.
Study: NCT06168851
Drug: Anti-CD38 antibody Injection
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment.
Study: NCT05944562
Drug: Tulmimetostat
Normalized name: Tulmimetostat
DrugBank: Tulmimetostat (DB19446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients should take CPI-0209 at approximately the same time every morning in a fasted state (no food for 2 hours prior and 1 hour following CPI-0209 dosing). Each dose of CPI-0209 should be taken with a glass of water and consumed over as short a time as possible.
Study: NCT06391853
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A venous line will be installed and an MRI-compatible EEG Cap (32 scalp electrodes) will be installed with conductive gel between the scalp and the electrode.~Participants will receive 2 Intranasal spray. Participants will then be installed in the PET/MRI camera. At 30 min post INI administration, a continuous infusion of FDG will be started, along with dynamic PET acquisition while recording EEG and fMRI sequences. Participant will be asked to rest, eyes opened and awake to stay awake during the 55 minutes.~At the end of the neuroimaging data acquisition, participants will be freed from EEG Cap and will undergo neuropsychologic evaluation.The final part of neuropsychological evaluation will be performed on week later, on the phone.. The total study time for each scanning day will be around 3h.
Study: NCT05935033
Drug: Emraclidine
Normalized name: Emraclidine
DrugBank: Emraclidine (DB18706)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT05578976
Drug: Epcoritamab
Normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Injection (SC)
Study: NCT05578976
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV Infusion
Study: NCT05578976
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Infusion
Study: NCT05578976
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral; Tablet
Study: NCT05579249
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive semaglutide 2.4 milligrams (mg) subcutaneous (s.c.) injection once weekly for 52 weeks.
Study: NCT05579249
Drug: Orlistat
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
Study: NCT05579249
Drug: Phentermine/Topiramate
Normalized name: PHENTERMINE/TOPIRAMATE
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
Study: NCT05579249
Drug: Naltrexone/Bupropion
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
Study: NCT05579249
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
Study: NCT06515470
Drug: BTX-9341
Normalized name: BTX-A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Daily oral dose in 28-day cycles until maximum tolerated dose (MTD) or maximum evaluable dose (MED) determined
Study: NCT06515470
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg intramuscular injections on Day 15 and then every 28 days
Study: NCT06515470
Drug: BTX-9341
Normalized name: BTX-A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Daily oral dose in 28-day cycles using dose determined in Part A
Study: NCT06522386
Drug: Pirtobrutinib
Normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by mouth
Study: NCT06522386
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by vein (IV)
Study: NCT06522386
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by mouth
Study: NCT06222489
Drug: 89Zr-Patritumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Patritumab (DB12090)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Day 1, day 3, day 6, day 11 and day 26 of first course
Study: NCT05929794
Drug: Metronidazole 0.75% Topical Gel
Normalized name: Metronidazole 0.75% Topical gel
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half of enrolled subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm. Color will only be measured at baseline. Micropatch application will occur at 2 sites, followed by application of metronidazole gel and then covered with an occlusive covering. One site will be covered with an occlusive covering only (no micropatch or gel). At 48 hours occlusive coverings and gel are removed and electrical resistance measurements are repeated. Fresh gel and occlusive patches are reapplied. At 96 hours the patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis. After a minimum 7 days washout period, all of these procedures will be repeated again except that there will be no micropatch application at any of the 3 sites.
Study: NCT05929794
Drug: Metronidazole 0.75% Topical Cream
Normalized name: Metronidazole 0.75% Topical cream
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half of enrolled subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm. Color will only be measured at baseline. Micropatch application will occur at 2 sites, followed by application of metronidazole cream and then covered with an occlusive covering. One site will be covered with an occlusive covering only (no micropatch or cream). At 48 hours occlusive coverings and cream are removed and electrical resistance measurements are repeated. Fresh cream and occlusive patches are reapplied. At 96 hours the patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis. After a minimum 7 days washout period, all of these procedures will be repeated again except that there will be no micropatch application at any of the 3 sites.
Study: NCT06023862
Drug: Dostarlimab
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT06023862
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV) infusion
Study: NCT06023862
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous (IV) infusion
Study: NCT06023862
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV) infusion
Study: NCT06648889
Drug: Isatuximab
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cohort 1: All patients will receive two cycles of induction therapy with standard chemotherapy, Bortezomib and Isatuximab. Isatuximab maintenance may be administered in patients with CR until SCT, progression/relapse, unacceptable toxicity, physicians' decision to change treatment or withdrawal of consent.
Study: NCT06648889
Drug: Isatuximab
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cohort 2: All patients will receive at least one cycle with Isatuximab. Each cycle will be 4 weeks in duration. Isatuximab will be administered until SCT, hematologic relapse including extramedullary, unacceptable toxicity, physicians' decision, or withdrawal of consent.
Study: NCT04982848
Drug: Talzenna
Normalized name: Talzenna
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talzenna treatment under Korea regulatory approval indication/dosage
Study: NCT05579730
Drug: Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: combination ophthalmic solution
Study: NCT05579730
Drug: Brimonidine Tartrate 0.025%
Normalized name: BRIMONIDINE TARTRATE 0.025% OPH SOLN
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ophthalmic Solution